BioSpace News Archive

Conference call to discuss financial and operational results scheduled for Friday, November 13 at 8:30 a.m. U.S. Eastern Time

Kodiak Sciences Inc., a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced that management will present at the following upcoming virtual investor conferences:

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced that Maria Palasis, Ph.D., Lyra’s President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual London Healthcar

Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports financial results for the three and nine months ended September 30, 2020 and provides a business update.

Onconova Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing novel products to treat cancer, reported financial results for the quarter ended September 30, 2020 and provided a business update.

Aziyo Biologics, Inc., a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, has been awarded a group purchasing agreement with Premier Inc., for Premier’s Technology Breakthroughs Program.

Yield10 Bioscience, Inc., an agricultural bioscience company, reported financial results for the three and nine months ended September 30, 2020.

First look at preclinical data infrontotemporal dementia with progranulin mutations (GRN-FTD)and new amyotrophic lateral sclerosis (ALS) program

Graybug Vision, Inc., a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, provided an update on recent corporate developments and reported financial results for the three and nine months ended September 30, 2020.

Akero Therapeutics, Inc., a cardio-metabolic non-alcoholic steatohepatitis company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, reported third quarter financial results for the period ending September 30, 2020.